COLPLATIR® as a Novel Therapeutic Adjuvant for the Management of Irritable Bowel Syndrome (IBS)

Umberto Di Maio; Antonino Bagnulo; Andrea Cerciello*

Umberto Di Maio, Antonino Bagnulo and Andrea Cerciello*

Volume4-Issue12
Dates: Received: 2023-11-16 | Accepted: 2023-12-01 | Published: 2023-12-04
Pages: 1645-1651

Abstract

Irritable Bowel Syndrome (IBS) is a chronic disorder of the gastrointestinal system characterized by abdominal pain or discomfort and associated with different comorbidities like fibromyalgia, chronic pelvic pain, gastroesophageal reflux disease, anxiety and depression. In this study, the effects of COLPLATIR®, a nutraceutical product with a patented technology named BUTIRESOLV®, were investigated. In vivo and Ex-vivo analysis were carried out on IBS with diarrhoea (IBS-D) mouse model by intracolonic administration of Oil of Mustard (OM). Positive results have been obtained, thus demonstrating that the nutraceutical COLPLATIR® could reduce the abnormalities in intestinal motility, as observed in IBS.

FullText HTML FullText PDF DOI: 10.37871/jbres1844

Certificate of Publication

Copyright

How to cite this article

Di Maio U, Bagnulo A, Cerciello A. COLPLATIR® as a Novel Therapeutic Adjuvant for the Management of Irritable Bowel Syndrome (IBS). J Biomed Res Environ Sci. 2023 Dec 04; 4(12): 1645-1651. doi: 10.37871/jbres1844, Article ID: JBRES1844, Available at: https://www.jelsciences.com/articles/jbres1844.pdf

Subject area(s)

Gastroenterology

References

Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015 Mar 3;313(9):949-58. doi: 10.1001/jama.2015.0954. PMID: 25734736.
Agréus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995 Sep;109(3):671-80. doi: 10.1016/0016-5085(95)90373-9. PMID: 7657095.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061. Erratum in: Gastroenterology. 2006 Aug;131(2):688. PMID: 16678561.
Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol. 2008 May;103(5):1241-8. doi: 10.1111/j.1572-0241.2007.01755.x. Epub 2008 Apr 16. PMID: 18422817.
El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol. 2012 Oct 7;18(37):5151-63. doi: 10.3748/wjg.v18.i37.5151. PMID: 23066308; PMCID: PMC3468846.
Di Maio U, Bagnulo A, Cerciello A. The Neuroprotective Effect of senydem®: A new therapeutic approach for the management of cognitive impairment in alzheimer’s disease. Biomed J Sci & Tech Res. 2023;53(2). doi: 10.26717/BJSTR.2023.53.008387.
Camerlingo A, Di Maio U, Cerciello A. Pain relief effect of Crackdol® fast foam in osteoarticular disorders. J Clin Stud Med Case Rep. 2023 Sep;10: 193. doi: 10.24966/CSMC- 8801/1000193.
Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev. 1990 Apr;70(2):567-90. doi: 10.1152/physrev.1990.70.2.567. PMID: 2181501.
Scarpellini E, Lauritano EC, Lupascu A, Petruzzellis C, Novi ML, Roccarina D, Gasbarrini A. Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome. Digestive and Liver Disease Supplements. 2007;1(1):19-22. doi:10.1016/s1594- 5804(08)60006-6.
Vernia P, Annese V, Bresci G, d'Albasio G, D'Incà R, Giaccari S, Ingrosso M, Mansi C, Riegler G, Valpiani D, Caprilli R; Gruppo Italiano per lo Studio del Colon and del Retto. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest. 2003 Mar;33(3):244-8. doi: 10.1046/j.1365- 2362.2003.01130.x. PMID: 12641543.
Rao YS, Mathew MK, Potty SN. Tamarindus indica. Indian Journal of Arecanut, Spices and Medicinal Plants. 1999;1:127-45.
Viola H, Wasowski C, Levi de Stein M, Wolfman C, Silveira R, Dajas F, Medina JH, Paladini AC. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors- ligand with anxiolytic effects. Planta Med. 1995 Jun;61(3):213-6. doi: 10.1055/s-2006- 958058. PMID: 7617761.
Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 2007 Sep;85(9):933-42. doi: 10.1139/Y07-083. PMID: 18066140.
Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. 2004 Dec;10(6):1015-8. doi: 10.1089/acm.2004.10.1015. PMID: 15673996.
Kimball ES, Palmer JM, D'Andrea MR, Hornby PJ, Wade PR. Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice. Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1266-73. doi: 10.1152/ajpgi.00444.2004. Epub 2005 Feb 3. PMID: 15691868.
Capasso R, Orlando P, Pagano E, Aveta T, Buono L, Borrelli F, Di Marzo V, Izzo AA. Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels. Br J Pharmacol. 2014 Sep;171(17):4026-37. doi: 10.1111/bph.12759. PMID: 24818658; PMCID: PMC4243976.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, Hoyer D, Insel PA, Izzo AA, Ji Y, MacEwan DJ, Sobey CG, Stanford SC, Teixeira MM, Wonnacott S, Ahluwalia A. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol. 2018 Apr;175(7):987-993. doi: 10.1111/bph.14153. PMID: 29520785; PMCID: PMC5843711.
Lührs H, Gerke T, Müller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002 Apr;37(4):458-66. doi: 10.1080/003655202317316105. PMID: 11989838.
Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991 Oct;101(4):927-34. doi: 10.1016/0016-5085(91)90717-y. Erratum in: Gastroenterology 1992 Feb;102(2):746. PMID: 1889716.
Ali N, Shah S. Spasmolytic Activity of Fruits of Tamarindus indica L. J Young Pharm. 2010 Jul;2(3):261-4. doi: 10.4103/0975-1483.66805. PMID: 21042482; PMCID: PMC2964778.
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008 Jan 15;27(2):104-19. doi: 10.1111/j.1365-2036.2007.03562.x. Epub 2007 Oct 25. PMID: 17973645.
Gaudier E, Jarry A, Blottière HM, de Coppet P, Buisine MP, Aubert JP, Laboisse C, Cherbut C, Hoebler C. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1168-74. doi: 10.1152/ajpgi.00219.2004. Epub 2004 Aug 12. PMID: 15308471.
Finnie IA, Dwarakanath AD, Taylor BA, Rhodes JM. Colonic mucin synthesis is increased by sodium butyrate. Gut. 1995 Jan;36(1):93-9. doi: 10.1136/gut.36.1.93. PMID: 7890244; PMCID: PMC1382360.
Shinomiya K, Inoue T, Utsu Y, Tokunaga S, Masuoka T, Ohmori A, Kamei C. Hypnotic activities of chamomile and passiflora extracts in sleep-disturbed rats. Biol Pharm Bull. 2005 May;28(5):808-10. doi: 10.1248/bpb.28.808. PMID: 15863883.
Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 2007 Sep;85(9):933-42. doi: 10.1139/Y07-083. PMID: 18066140.
Yoo DY, Choi JH, Kim W, Yoo KY, Lee CH, Yoon YS, Won MH, Hwang IK. Effects of Melissa officinalis L. (lemon balm) extract on neurogenesis associated with serum corticosterone and GABA in the mouse dentate gyrus. Neurochem Res. 2011 Feb;36(2):250-7. doi: 10.1007/s11064-010-0312-2. Epub 2010 Nov 13. PMID: 21076869.